TABLE 2.

Humoral and T-cellular titers at study time points two (T2) and six (T3) months in different vaccine combinations.

Var	Type of vaccines	Category	T2	T3	P-value
IgG-Ab Spike S1	3x BNT162b2	Median (IQR)	3.2 (3.2–4.6)	3.8 (3.2–16.7)	<0.001
	2x BNT162b2, 1x 1273	Median (IQR)	3.2 (3.2–3.2)	3.5 (3.2–52.5)	0.003
	2x 1273, 1x BNT162b2	Median (IQR)	3.2 (3.2–6.2)	22.8 (3.2–52.6)	0.003
	3x 1273	Median (IQR)	3.2 (3.2–5)	28.1 (3.2–209.4)	<0.001
	2x mRNA, 1x vector vaccine	Median (IQR)	3.2 (3.2–3.2)	3.2 (3.2–6)	0.181
	2x mRNA	Median (IQR)	3.2 (3.2–6.4)	3.6 (3.2–21.9)
RBD-IgG-Ab RBD	3x BNT162b2	Median (IQR)	3.8 (3.2–6.2)	10.2 (7.6–15.3)	0.088
	2x BNT162b2, 1x 1273	Median (IQR)	1.4 (1.1–4.8)	3.6 (1.6–21)	0.093
	2x 1273, 1x BNT162b2	Median (IQR)	0 (0–5.3)	4.2 (0–29.9)	0.5
	3x 1273	Median (IQR)	3.9 (1.9–7.7)	7.5 (0–58.2)	<0.001
	2x mRNA, 1x vector vaccine	Median (IQR)	2.7 (0–3.4)	0 (0–1.1)	0.529
	2x mRNA	Median (IQR)	4.5 (1.9–7.7)	3.9 (0–9.4)
IgA-Ab Spike S1	3x BNT162b2	Median (IQR)	0.3 (0.2–0.5)	0.4 (0.2–0.7)	0.156
	2x BNT162b2, 1x 1273	Median (IQR)	0.4 (0.2–0.7)	0.5 (0.3–1.3)	0.001
	2x 1273, 1x BNT162b2	Median (IQR)	0.3 (0.2–0.3)	0.3 (0.2–0.7)	0.289
	3x 1273	Median (IQR)	0.3 (0.2–0.5)	0.5 (0.3–1.4)	<0.001
	2x mRNA, 1x vector vaccine	Median (IQR)	0.3 (0.1–0.4)	0.3 (0.2–0.4)	0.313
	2x mRNA	Median (IQR)	0.4 (0.2–0.6)	0.3 (0.2–0.6)
Interferon-γ release assays (IGRA)	3x BNT162b2	Median (IQR)	13.3 (0.9–38.9)	8.3 (1.3–60.3)	0.266
	2x BNT162b2, 1x 1273	Median (IQR)	0 (0–0.1)	17.2 (5.5–43.4)	0.5
	2x 1273, 1x BNT162b2	Median (IQR)	29.3 (29.3–152.8)
	3x 1273	Median (IQR)	23.6 (3.7–151.4)	28.6 (6.1–200.4)	0.952
	2x mRNA,1x vector vaccine	Median (IQR)	7.1 (0–183.6)	11.9 (7.1–31.3)	0.062
	2x mRNA	Median (IQR)	26.1 (11.8–444.3)	23.7 (5.8–107)

This table compares the average titer levels (median/interquartile range = IQR) on T3 with T2 (different columns) for the different anti-SpikeS1 IgA, IgG, RBD-IgG antibodies as well as for cellular immunity via Interferon-γ release assay = IGRA measurements in patients who received different combinations of mRNA vaccine (different rows). For this evaluation, all participants with asymptomatic* or documented symptomatic** COVID-19 disease before and during vaccination up to T3 (6 months) were excluded.

BNT162b2 = BNT162b2-mRNA or tozinameran or brand name Comirnaty; 1273 = 1273-mRNA or brand name Spikevax.

*Asymptomatic COVID-19 disease definition–neither knowledge nor symptoms of COVID-19 disease, but IgG-antibody reaction to nucleocapsid (T0, T2, or T3) or the Spike protein subunit S1 (only T0) of the SARS-CoV-2 virus is positive.

**Symptomatic COVID-19 disease definition–SARS-CoV-2 PCR positive patients with clinical symptoms.